Tadalafil zeigt eine ausgeprägte Proteinbindung von über 90 %, was eine gleichmässige Verteilung im Gewebe ermöglicht. Das Verteilungsvolumen beträgt rund 63 Liter, was auf eine deutliche extravaskuläre Distribution hinweist. Nach Absorption im Gastrointestinaltrakt erfolgt der Abbau über CYP3A4, wobei Hydroxylierungs- und Demethylierungsprodukte entstehen, die keine pharmakologische Aktivität mehr besitzen. Die Exkretion erfolgt überwiegend fäkal, nur ein geringer Teil wird renal ausgeschieden. Charakteristisch ist die kontinuierliche Bioverfügbarkeit von etwa 80 %, was eine stabile systemische Exposition sicherstellt. Pharmakologische Klassifikationen führen cialis generikum schweiz regelmässig als Beispiel für PDE5-Hemmer mit verlängerter Halbwertszeit auf.
Surgery.med.sc.edu
Medical Information Database
Name: __________________________________________ Date: __________________ Reason for seeing doctor: ___________________________________________________ Referring Physician: _______________________________________________________ Were you seen in the Emergency Room? YES NO ___ Richland ___ Baptist ___ Lexington ___ Providence ___ Providence NE ___ Other Date of accident or injury: _______________ If not accident or injury, date the symptoms began: __________________ Current physician, pediatrician, or family doctor, if you have one: __________________ Previous Medical History
List all known allergies: ____________________________________________________ ________________________________________________________________________ Do you have a Latex Allergy/Sensitivity? YES NO List all medications you are taking and reason you are taking it (including Aspirin, Ibuprofen, Motrin, NSAID, Goody Powder, Vitamins, herbal Medication, etc.): _______ _______________________________________________________________________ _______________________________________________________________________ _______________________________________________________________________ List any medications that you cannot take: _____________________________________ _______________________________________________________________________ Immunizations
Please indicate date (month and year) of last immunization. Tetanus Booster ____________
Patient Name: ____________________________________ Date: __________________
Current Medical Problems
Please “X” YES or NO YES NO
___ ___ Breast Disease ___ ___ Other, if any please explain: ________________________________________ Review of Systems
Please “X” YES or NO YES NO
Previous Hospitalizations
Date
______________________________________________________
______________________________________________________
______________________________________________________
______________________________________________________
Patient Name: ____________________________________ Date: __________________ Past Surgical History
Date
Social History
Do you use tobacco products of any kind? YES / NO Amount / Frequency: __________ Do you drink alcohol? YES / NO Amount / Frequency: __________________________ Do you use illegal drugs? YES / NO Amount / Frequency: _______________________ Occupation: _____________________________________________________________ Living Situation: _________________________________________________________ Family History
Please “X” YES or NO and relationship YES NO Relationship
Reviewed and updated on _____________ By _________
Reviewed and updated on _____________ By _________
E. Comments from Survey Respondents In this appendix, we provide selected comments that we received from surveyrespondents. The comments have been organized according to the topicsdiscussed in Chapter 5 and are divided into three sections—general commentsfrom direct-care system prescribers; comments from direct-care prescribersspecifically in response to a question on changes they would make
Medical Information Database